ArticleFrontiers in allergy2026
Clinical and immunological markers of peanut allergy severity and tolerance in children.
Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Improved diagnostic tools are needed to assess the risk of severe peanut allergy (PA) and/or predict its resolution. Methods: This prospective multicenter cross-sectional study with follow-up elements (2020-2024) included children aged 3 months-18 years with confirmed PA. Diagnosis relied on clinical history, skin-prick test wheals (SPT), peanut sIgE, and/or oral food challenge (OFC). Children with isolated systemic cutaneous reactions (World Allergy Organization-WAO grade 1) were compared with children with WAO grade ≥2 reactions. Basophil activation testing (BAT) and component-resolved diagnostics were performed in all participants, and OFC assessed tolerance in selected children. Results: Among 51 children (24 WAO grade 1 and 27 grade 2-5), those with anaphylaxis had larger SPT wheals ( Conclusion: Several biomarkers, including peanut SPT, sIgE, Ara h 1, Ara h 2, Ara h 6, and BAT showed moderate discrimination between systemic cutaneous reactions and anaphylaxis, while peanut sIgE, Ara h 2, and Ara h 6 were associated with clinical tolerance. Evaluating these biomarkers may help reduce the need for OFCs in selected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.